Evidence map›Paper›PMID 31489788›Full record

SynthesisCancer medicine2019

Efficacy and safety of different fractions in stereotactic body radiotherapy for spinal metastases: A systematic review.

Yining Gong, Lingyi Xu, Hongqing Zhuang, Liang Jiang, Feng Wei, Zhongjun Liu, Yan Li, Miao Yu, Kaiwen Ni, Xiaoguang Liu

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Stereotactic body radiotherapy for spinal metastases: a review.Medical oncology (Northwood, London, England) · 2022
    Review
  10. Long-term outcomes of spinal SBRT. Is it important to select the treatment time?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  11. Article
  12. [Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : A phase III multi-center trial].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yining GongDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.ORCID 0000-0002-7320-0252
Lingyi XuEight-Year-Program, Grade 2015, Health Science Center, Peking University, Beijing, China.
Hongqing ZhuangDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, China.
Liang JiangDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Feng WeiDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Zhongjun LiuDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Yan LiDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Miao YuDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Kaiwen NiResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Xiaoguang LiuDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the treatment of spinal metastases, stereotactic body radiotherapy (SBRT) delivers precise, high-dose radiation to the target region while sparing the spinal cord. A range of doses and fractions had been reported; however, the optimal prescribed scheme remains unclear.

methodsTwo reviewers performed independent literature searches of the PubMed, EMBASE, Cochrane Database, and Web of Science databases. Articles were divided into one to five fractions groups. The Methodological Index for Non-randomized Studies (MINORS) was used to assess the quality of studies. Local control (LC) and overall survival (OS) were presented for the included studies and a pooled value was calculated by the weighted average.

resultsThe 38 included studies comprised 3,754 patients with 4,731 lesions. The average 1-year LCs for the one to five fractions were 92.7%, 84.6%, 86.8%, 82.6%, and 80.6%, respectively. The average 1-year OS for the one to five fractions were 53.0%, 70.4%, 60.1%, 48%, and 80%, respectively. The 24 Gy/single fraction scheme had a higher 1-year LC (98.1%) than those of 24 Gy/two fractions (85.4%), 27 Gy/three fractions (84.9%), and 24 Gy/three fractions (89.0%). The incidence of vertebral compression fracture was 10.3%, with 10.7% in the single-fraction group and 10.1% in the multi-fraction group. The incidence of radiation-induced myelopathy was 0.19%; three and two patients were treated with single-fraction and multi-fraction SBRT, respectively. The incidence of radiculopathy was 0.30% and all but one patient were treated with multi-fraction SBRT.

conclusionsSBRT provided satisfactory efficacy and acceptable safety for spinal metastases. Single-fraction SBRT demonstrated a higher local control rate than those of the other factions, especially the 24 Gy dose. The risk of vertebral compression fracture (VCF) was slightly higher in single-fraction SBRT and more patients developed radiculopathy after multi-fraction SBRT.

Indexed as

Dose Fractionation, RadiationFemaleFractures, CompressionHumansMalePrognosisRadiculopathyRadiosurgerySpinal Cord DiseasesSpinal NeoplasmsTreatment Outcomemulti-fractionsingle-fractionspinal metastasesstereotactic body radiotherapystereotactic radiosurgerysystematic review

Identifiers

PMID31489788
PMCPMC6797563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.